Ovarian cancer in elderly patients: Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: A gynecologic cancer intergroup (GCIG) CALYPSO sub-study

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2417-2423

  Kurtz, J E ^a   Kaminsky, M C ^b   Floquet, A ^c   Veillard, A S ^d   Kimmig, R ^e   Dorum, A ^f   Elit, L ^g   Buck, M ^h   Petru, E ⁱ   Reed, N ^j   Scambia, G ^k   Varsellona, N ^l   Brown, C ^d   Pujade lauraine, E ^m  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c INSTITUT BERGONIÉ   (France)

^d National Health and Medical Research Council Clinical Trials Centre   (Australia)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g JURAVINSKI CANCER CENTRE   (Canada)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^k CATHOLIC UNIVERSITY   (Italy)

^l AOR Villa Sofia Cervello ^*  (Italy)

^m UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Carboplatin; Elderly; Ovarian cancer; Paclitaxel; Pegylated liposomal doxorubicin; Relapse

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; AGE; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 80155164018     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr001     Document Type: Article

References (18)

1. Uyar D, Frasure HE, Markman M, von Gruenigen, VE. Treatment patterns by decade of life in elderly women (≥ 70 years of age) with ovarian cancer. Gynecol Oncol 2005; 98: 403-408.
2. Thigpen T, Brady MF, Omura GA et al. Age as a prognostic factor in ovarian carcinoma. Cancer 1993; 71: 606-614.
3. Gershenson DM, Mitchell MF, Atkinson N et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer 1993; 71: 638-643.
4. Wimberger P, Lehmann N, Kimmig R et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Arbeitsgemeinshaft. Gynecol Oncol 2006; 100: 300-307.
5. Bruchim I, Altaras M, Fishman A. Age contrasts in clinical characteristics and patterns of care in patients with epithelial ovarian cancer. Gynecol Oncol 2002; 86: 274-278.
6. Eisenhauer EL, Tew WP, Levine DA et al. Response and outcomes in elderly patients with stage IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 2007; 106: 381-387.
7. Trédan O, Geay J-F, Touzet S et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 2007; 18: 256-262.
8. Hilpert F, du Bois A, Greimel ER et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or= 70 years with advanced ovarian cancer-a study by the AGO OVAR Germany. Ann Oncol 2007; 18(2): 282-287.
9. Zola P, Ferrero A. Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients? Ann Oncol 2007; 18(2): 213-214.
10. Pignata S, Breda E, Scambia G et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian Cancer (MITO-5) study. Crit Rev Oncol Hematol 2008; 66(3): 229-236.
11. Hershman D, Jacobson JS, McBride R et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004; 94: 540-549.
12. Steer CB. Chemotherapy for ovarian cancer in the older adult. Curr Treat Options Oncol 2009; 10: 159-170.
13. Pignata S, Ferrandina G, Scarfone G et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol 2009; 71: 233-241.
14. Gronlund B, Høgdall C, Hansen HH, Engelholm SA. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002; 94(7): 1961-1967.
15. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28(20): 3323-3329.
16. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263-268.
17. Freyer G, Geay J-F, Touzet S et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma. Ann Oncol 2005; 16: 1795-1800.
18. Kurtz JE, Heitz D, Kurtz-Illig V, Dufour P. Geriatric oncology: how far have we gone and what are the next steps? Oncology 2009; 77: 147-156.